<DOC>
	<DOCNO>NCT02878330</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics ( PK ) , antidrug antibody ( ADA ) response MEDI8897 healthy preterm infant 29 35 week gestational age enter first RSV season .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy MEDI8897 Prevention Medically Attended RSV LRTI Healthy Preterm Infants .</brief_title>
	<detailed_description>This pivotal Phase 2b study determine MEDI8897 efficacious reduce medically attend RSV-confirmed low respiratory tract infection ( LRTI ) healthy preterm infant enter first RSV season . The population enrol healthy preterm infant bear 29 week 0 day 34 week 6 day gestational age ( GA ) would receive RSV prophylaxis . A total 1500 infant randomize 2:1 receive either MEDI8897 placebo . Subjects follow 360 day dose . Enrollment plan approximately 197 site across USA , Canada , Europe , Southern Hemisphere .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key 1 . Healthy infant born 29 week 0 day 34 week 6 day GA 2 . Infants enter first full RSV season time screen Key 1 . Meets American Academy Pediatrics ( AAP ) local criterion receive commercial palivizumab 2 . Any fever ( ≥ 100.4°F [ ≥ 38.0°C ] , regardless route ) low respiratory illness within 7 day prior randomization 3 . Acute illness ( define presence moderate severe sign symptom ) time randomization 4 . Active RSV infection ( child signs/symptoms respiratory infection must negative RSV test ) know prior history RSV infection 5 . Receipt palivizumab RSV monoclonal antibody RSV vaccine , include maternal RSV vaccination</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Respiratory Syncytial Virus , RSV</keyword>
	<keyword>Preterm Infants</keyword>
	<keyword>Lower Respiratory Tract Infection</keyword>
</DOC>